AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04003896
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc.
Trial: NCT06013098
Drug: 30%Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
Trial: NCT06013098
Drug: 60%Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
Trial: NCT05081986
Drug: Cycloserine
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloserine 100mg
Trial: NCT04283019
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD will be orally ingested
Trial: NCT04283019
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC will be orally ingested
Trial: NCT05721287
Drug: SBS-1000
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBS-1000 administered as a single continuous IV infusion over 60 minutes
Trial: NCT04524208
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib is administered orally at the dose of 60 mg per day..
Trial: NCT05545124
Drug: Donafenib + Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
Trial: NCT06704763
Drug: Orforglipron
RxNorm normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06704763
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT06704763
Drug: Quinidine
RxNorm normalized name: Quinidine
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06705387
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
Trial: NCT04311671
Drug: Moxidectin
RxNorm normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg tablets, encapsulated for blinding
Trial: NCT04311671
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg tablets, encapsulated for blinding
Trial: NCT04311671
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets
Trial: NCT03523338
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive apalutamide 240 mg orally once daily.
Trial: NCT06733519
Drug: Nalmefene
RxNorm normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Th-104 Nalmefene Mucoadhesive Buccal strip
Trial: NCT06731907
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
Trial: NCT06731907
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m\^2 IV infusion.
Trial: NCT06731907
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 100mg/m\^2 IV infusion.
Trial: NCT06731907
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500mg/m\^2 IV infusion.
Trial: NCT04935684
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.
Trial: NCT05100160
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06372184
Drug: Washed Microbiota Transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take four capsules containing washed microbiota once a day for five consecutive days
Trial: NCT06346925
Drug: Herombopag Olamine Tablets
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.
Trial: NCT03834571
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03834571
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03834571
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05407311
Drug: 64Cu-SAR-BBN
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64Cu-SAR-BBN
Trial: NCT05137119
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin
Trial: NCT05137119
Drug: Penicillin
RxNorm normalized name: Penicillin
DrugBank: Nafcillin (DB00607)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: benzylpenicillin
Trial: NCT05137119
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin or Daptomycin
Trial: NCT06018467
Drug: Dasatinib 100 Mg Oral Tablet
RxNorm normalized name: Dasatinib 100 mg oral tablet
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb
Trial: NCT05294250
Drug: XC8
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
Trial: NCT05042258
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 week dupilumab administration
Trial: NCT04168879
Drug: Bupivacaine 0.5% Preservative-Free Injectable Solution
RxNorm normalized name: BUPivacaine 0.5% preservative-free injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
Trial: NCT06632717
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
Trial: NCT06632717
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
Trial: NCT06008275
Drug: Neratinib Oral Tablet
RxNorm normalized name: neratinib Oral Tablet
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 240mg oral daily. Dosing will follow standard dose escalation procedures
Trial: NCT06008275
Drug: Ruxolitinib Oral Tablet
RxNorm normalized name: ruxolitinib Oral Tablet
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
Trial: NCT04187547
Drug: Tricaprilin
RxNorm normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)
Trial: NCT05088785
Drug: FES
RxNorm normalized name: FESO
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FES PET imaging.
Trial: NCT00000974
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05006781
Drug: DAOIB
RxNorm normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The DAOIB dose in each group will be fixed during the 24 weeks duration
Trial: NCT05507411
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
Trial: NCT05404529
Drug: Tavapadon
RxNorm normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00610051
Drug: Alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: central venous access continuous delivery with 500mcg/48 hours in active arm
Trial: NCT03890341
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
Trial: NCT03890341
Drug: JNJ-64530440
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
Trial: NCT00000218
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05779267
Drug: NRX-101
RxNorm normalized name: NRX-1074
DrugBank: INBRX-101 (DB18384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine/lurasidone fixed dose combination
Trial: NCT04200066
Drug: Temozolomide, Tamoxifen, Maprotiline
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
Trial: NCT00530361
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001112
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001112
Drug: Interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06516939
Drug: bFGF
RxNorm normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-face randomized control
Trial: NCT06516939
Drug: Bovine Basic Gel
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine Basic Gel
Trial: NCT00002026
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04836819
Drug: Lidocain
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
Trial: NCT04836819
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
Trial: NCT04836819
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
Trial: NCT05745857
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally administered
Trial: NCT05745857
Drug: Erbitux
RxNorm normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally administered
Trial: NCT04833023
Drug: Olanzapine Actavis 5mg orodispersible tablet
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).
Trial: NCT06635746
Drug: Vinpocetine
RxNorm normalized name: Vinpocetine
DrugBank: Vinpocetine (DB12131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of vinpocetine to assess tolerability.
Trial: NCT05221164
Drug: Aspirin 162 mg
RxNorm normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin 162 mg during pregnancy to prevent preeclampsia
Trial: NCT05808725
Drug: Amlodipine Freeze-Dried Powder for Oral Solution 5 mg
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
Trial: NCT06646666
Drug: All-trans retinoic acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg，tid，po (After apheresis and continued until post-infusion)
Trial: NCT06646666
Drug: zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160mg，bid，po (prior to apheresis and continued until post-infusion)
Trial: NCT06646666
Drug: CAR-T
RxNorm normalized name: CD5CAR-T
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cell therapy
Trial: NCT06646666
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 200 mg on D1, Q3W
Trial: NCT04978493
Drug: BI 706321
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 706321
Trial: NCT04978493
Drug: ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ustekinumab
Trial: NCT04733560
Drug: Bupivacaine Injectable Product
RxNorm normalized name: bupivacaine Injectable Product
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for pudendal nerve block in the intervention arm
Trial: NCT04667117
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab.
Trial: NCT06100497
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
Trial: NCT06100497
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
Trial: NCT06100497
Drug: Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mainly used for neoadjuvant treatment
Trial: NCT04815551
Drug: AV-380
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Trial: NCT00000216
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05959252
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
Trial: NCT05959252
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin protocol with target aPTT 50-70 seconds
Trial: NCT06078787
Drug: Olaparib 150 MG
RxNorm normalized name: olaparib 150 MG
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib should be dosed 2 x 150 mg tablets (300 BID)
Trial: NCT00218140
Drug: nicotine transdermal system
RxNorm normalized name: Nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05304910
Drug: Lu AG09222
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG09222 will be administered per schedule specified in the arm description.
Trial: NCT06099171
Drug: Cannabidiol and β-Caryophyllene Patch
RxNorm normalized name: Caryophyllene
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity